The strong revenue acceleration and narrowing losses suggest the company is gaining traction in the wound care market, supported by favorable Medicare reimbursement changes. Monitor upcoming quarters for continued sequential growth and progress toward breakeven, as the $1.0M loan provides limited runway given the $263K cash balance.
Price Chart
Executive Summary
Nuo Therapeutics reported Q1 2026 total revenue of $1.3M, up 169% YoY from $484K, driven by Aurix product sales growth of over 30% sequentially. Net loss narrowed to $618K from $746K YoY, while operating loss improved to $446K from $745K. The company secured a $1.0M loan facility for working capital as it approaches breakeven.
Key Financial Metrics
Key Facts
- Total revenue of $1,302,115 for Q1 2026, up 169% from $484,381 in Q1 2025
- Aurix branded product revenues up over 30% sequentially vs Q4 2025
- Net operating loss narrowed to $446,466 from $745,147 YoY
- Net loss of $618,466 vs $746,128 in prior year period
- Entered into Loan and Security Agreement with initial funding of $1.0 million
- Cash balance of $263,827 at March 31, 2026, down from $548,946 at year-end 2025
- Stockholders' deficit of $1,383,863 at quarter end
Financial Impact
Revenue growth of 169% YoY to $1.3M; operating loss improvement of 40% to $446K
Risk Factors
- Cash balance of only $263,827 with stockholders' deficit of $1.4M raises going-concern risk
- Dependence on continued reimbursement tailwinds and market disruption from skin substitute changes
- Limited operating history at current revenue scale; breakeven not yet achieved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017116 |
| Document: aurx20260514_8k.htm | 0001437749-26-017116 |
| Document: 0001437749-26-017116-index-headers.html | 0001437749-26-017116 |
| Document: 0001437749-26-017116-index.html | 0001437749-26-017116 |
| Document: 0001437749-26-017116.txt | 0001437749-26-017116 |
| 8-K Data (Synthetic) | 0001437749-26-017116 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.30 | awaiting T+20 | — | $1.30 (−0.00%) |
Aug 17, 2026 10w ago | 8-K | $1.00 $1.25 | ▲ +25.00% | ▲ +26.53% | $1.30 (+30.00%) |
May 14, 2026 23w ago | 8-K | $1.35 $0.9674 | ▼ −28.34% | ▼ −30.46% | $1.30 (−3.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers